Clinical Trial RTOG 0920
- A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
- Principal Investigator
- Eric Donnelly
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.RTOG 0920
- The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone versus radiation therapy and cetuximab on head and neck cancer after surgery.
- It is standard treatment to remove head and/or neck tumors surgically when able to do so. After surgery it is common to have radiation therapy to help stop tumors from growing back or spreading to other parts of the body. Cetuximab is a drug that may slow down or prevent tumor growth. It works by blocking certain pathways that lead to tumor growth. This study will see if the addition of this drug with radiation therapy can improve overall outcomes over radiation alone.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have had surgery for a head and/or neck tumor.
- Participants with primary hypopharynx tumors are not eligible.
- Description of Treatment
- There are two groups in this study, Group 1 and Group 2. Participants will be randomized like flipping a coin)into one or the other group. Both groups will receive radiation therapy for about 6 weeks. Group 2 will be given cetuximab intravenously (through a vein) once a week and may receive up to 11 doses.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Eric Donnelly
- Randomized Feasibility Study of Dilator Use and an Educational Program to Increase Compliance after Vaginal Brachytherapy for Endometrial Cancer
- Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
- A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902/GOG-0274/RTOG 1174)
- A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
last updated: 24-May-16 06:29 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.